Brought to you by 
Zenyaku gets Japanese rights to blisibimod from Anthera
Jan 2015
Executive Summary
Anthera Pharmaceuticals Inc. granted Zenyaku Kogyo Co. Ltd. exclusive rights to develop and sell subcutaneous blisibimod in Japan for IgA nephropathy and systemic lupus erythematosus. The deal also includes an option for rights in additional Asian countries, including China, Hong Kong, Singapore, Taiwan, the Philippines, Thailand, Malaysia, Vietnam, Indonesia, and South Korea.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Intra-Biotech Deal
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zenyaku gets Japanese rights to blisibimod from Anthera
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice